Treating Newly Diagnosed Metastatic NSCLC with No Actionable Mutations in the First Line

The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.